COPD: Journal of Chronic Obstructive Pulmonary Disease

PAOG - New Independent CBD Research Appears To Support PAOG RespRx Research

Retrieved on: 
Tuesday, October 20, 2020

RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD derived from a patented cannabis extraction method- U.S. Patent No.

Key Points: 
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD derived from a patented cannabis extraction method- U.S. Patent No.
  • In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate.
  • Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG FDA Application Process For Respiratory Cannabis Drug Treatment Update Scheduled This Friday

Retrieved on: 
Tuesday, October 20, 2020

PAOG announced last week that it anticipates soon entering into an agreement with a contract research organization (CRO) making a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval.

Key Points: 
  • PAOG announced last week that it anticipates soon entering into an agreement with a contract research organization (CRO) making a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval.
  • On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method- U.S. Patent No.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG Expects To Finalize CRO Engagement For Cannabis Drug Within Next Two Weeks

Retrieved on: 
Thursday, October 15, 2020

PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks.

Key Points: 
  • PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks.
  • The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval.
  • On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method- U.S. Patent No.

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

Retrieved on: 
Wednesday, September 23, 2020

Simplici-T1 was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D.

Key Points: 
  • Simplici-T1 was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D.
  • The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes.
  • vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimers disease, and inflammatory disorders.
  • vTvs development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases.

vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting

Retrieved on: 
Wednesday, September 16, 2020

The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes.

Key Points: 
  • The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes.
  • The positive topline results from the learning phase - Part 1 were reported in June 2019.
  • vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimers disease, and inflammatory disorders.
  • vTvs development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases.

Massey Yardley Chrysler Dodge Jeep Ram Fiat Donates $2 Million to Holy Cross Health to Fund Expansion of Research and Treatment for Chronic Obstructive Pulmonary Disease

Retrieved on: 
Tuesday, September 15, 2020

PLANTATION, Fla., Sept. 15, 2020 /PRNewswire/ --Mr. Herb Yardley of Massey Yardley CDJRF is all too familiar with Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • PLANTATION, Fla., Sept. 15, 2020 /PRNewswire/ --Mr. Herb Yardley of Massey Yardley CDJRF is all too familiar with Chronic Obstructive Pulmonary Disease (COPD).
  • When his late wife, Catherine Yardley, was first diagnosed with the disease they didn't know where to turn.
  • We hope to begin correcting that by establishing a pulmonary center at Holy Cross Health."
  • The $2 million donation will establish the Catherine Yardley Pulmonary Center of Excellence at Holy Cross Health, a non-profit hospital.

Pulse Oximeter Market Size Worth USD 3,534.4 Million by 2027 | CAGR of 7.1%: Emergen Research

Retrieved on: 
Tuesday, September 15, 2020

- Pulse Oximeter Market Size USD 2,180.9 million in 2019, Pulse Oximeter Market Growth - CAGR of 7.1%, Pulse Oximeter Industry Trends Prevalence of Congenital Heart Disease (CHD) and Chronic Obstructive Pulmonary Disease (COPD), potential investment opportunities and technological advancements.

Key Points: 
  • - Pulse Oximeter Market Size USD 2,180.9 million in 2019, Pulse Oximeter Market Growth - CAGR of 7.1%, Pulse Oximeter Industry Trends Prevalence of Congenital Heart Disease (CHD) and Chronic Obstructive Pulmonary Disease (COPD), potential investment opportunities and technological advancements.
  • - Technological progress in pulse oximeter devices, prevalence of neonatal conditions with favorable reimbursement scenarios are expected to fuel the market growth
    VANCOUVER, B.C., Sept. 15, 2020 /PRNewswire/ -- The global pulse oximeter market is expected to reach USD 3,534.4 Billion by 2027, according to a new report by Emergen Research.
  • The increasing frequency of hypertension, asthma, chronic obstructive pulmonary disease (COPD), diabetes, sleep apnea, and cardiac arrhythmia, among other diseases, contribute to the growth prospects of pulse oximeter market.
  • To get leading market solutions, visit the link below:
    Emergen Research have segmented the global Pulse Oximeter Market on the basis of product, sensor type, end-uses, and region:
    Product Outlook (Revenue in Million USD; 20172027)

Gala Therapeutics Announces Publication of Multicenter Study of the Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis

Retrieved on: 
Thursday, September 3, 2020

MENLO PARK, Calif., Sept. 3, 2020 /PRNewswire/ --Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx Bronchial Rheoplasty System for chronic bronchitis.

Key Points: 
  • MENLO PARK, Calif., Sept. 3, 2020 /PRNewswire/ --Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx Bronchial Rheoplasty System for chronic bronchitis.
  • The prospective multi-center study evaluated the use of RheOx in patients with moderate to severe chronic bronchitis, a phenotype of Chronic Obstructive Pulmonary Disease(COPD), which affects more than 9 million Americans.
  • "There is a significant unmet need for a therapy that can improve the quality of life for chronic bronchitis patients," said Jonathan Waldstreicher, MD, CEO of Gala Therapeutics.
  • RheOx is a bronchoscopic system designed to reduce mucus-producing cells in patients with Chronic Bronchitis.

GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

Retrieved on: 
Wednesday, August 26, 2020

The global pulmonary drug delivery market is anticipated to register a CAGR of 5.06%, during the forecast years of 2019 to 2028.

Key Points: 
  • The global pulmonary drug delivery market is anticipated to register a CAGR of 5.06%, during the forecast years of 2019 to 2028.
  • Moreover, different forms of drug delivery systems, including inhalers and nebulizers, were introduced as alternative treatments for diverse lung conditions.
  • Similarly, the market for pulmonary drug delivery is fuelled by rising advancements in technology, and is projected to generate potential growth opportunities.
  • The global pulmonary drug delivery market growth is geographically analyzed through the Asia Pacific, Europe, North America, and the rest of the world.The Asia Pacific is projected to be the fastest-growing region, owing to the high incidence of chronic obstructive pulmonary disease (COPD), indicating significant socioeconomic problems.

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020

Retrieved on: 
Monday, August 24, 2020

LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new subgroup analysis from Phase 2b trials with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at the European Respiratory Society (ERS) International Congress on Tuesday, September 8, 2020.

Key Points: 
  • LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new subgroup analysis from Phase 2b trials with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at the European Respiratory Society (ERS) International Congress on Tuesday, September 8, 2020.
  • The abstracts are available on the ERS website and will be published in a supplement of the September 2020 edition of the peer reviewed journal, European Respiratory Journal.
  • Importantly, in non-reversible patients, a large, clinically meaningful and statistically significant improvement in QoL as measured by SGRQC Total Score was observed.
  • Ensifentrine has demonstrated significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharmas prior Phase 2 clinical studies in patients with moderate to severe COPD.